These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1918710)

  • 21. [Hemodynamic effects of i.v. diltiazem in primary pulmonary hypertension. Presentation of 2 clinical cases and review of the literature].
    Richichi G; Zingales LD; Cesari D; Roncella A
    Minerva Cardioangiol; 1986 Oct; 34(10):633-40. PubMed ID: 3808331
    [No Abstract]   [Full Text] [Related]  

  • 22. Invasive pharmacodynamic characterization of combined ibopamine and calcium blocker therapy for heart failure.
    Munger MA; Nara AR; Pospisil RA; Stoddard GJ; Schleman M
    Pharmacotherapy; 1993; 13(3):218-23. PubMed ID: 8100627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative cardiovascular effects of verapamil, nifedipine, and diltiazem during halothane anesthesia in swine.
    Kates RA; Zaggy AP; Norfleet EA; Heath KR
    Anesthesiology; 1984 Jul; 61(1):10-8. PubMed ID: 6742468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemodynamic effects of nifedipine in pulmonary hypertension.
    Klugmann S; Salvi A; Fioretti P; Camerini F
    G Ital Cardiol; 1982; 12(7):505-8. PubMed ID: 7169146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension.
    Rich S; Brundage BH; Levy PS
    Circulation; 1985 Jun; 71(6):1191-6. PubMed ID: 3995712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic application of calcium-channel antagonists for pulmonary hypertension.
    Packer M
    Am J Cardiol; 1985 Jan; 55(3):196B-201B. PubMed ID: 3881914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effects of verapamil, diltiazem, and nifedipine on hemodynamics and left ventricular function during acute myocardial ischemia in dogs.
    Urquhart J; Patterson RE; Bacharach SL; Green MV; Speir EH; Aamodt R; Epstein SE
    Circulation; 1984 Feb; 69(2):382-90. PubMed ID: 6690104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension.
    Woodmansey PA; O'Toole L; Channer KS; Morice AH
    Heart; 1996 Feb; 75(2):171-3. PubMed ID: 8673756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute effect of hydralazine administration on pulmonary artery hemodynamics in dogs with chronic heartworm disease.
    Atkins CE; Keene BW; McGuirk SM; Sato T
    Am J Vet Res; 1994 Feb; 55(2):262-9. PubMed ID: 8172418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decrease in pulmonary artery pressure with slow release nifedipine in Saudi patients with primary pulmonary hypertension.
    Ribeiro PA; Sivanandan V; Shaikh A; Chalak W; Zaman L; Duran CM
    Rev Port Cardiol; 1991 May; 10(5):413-8. PubMed ID: 1910877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid large artery remodeling following the administration and withdrawal of calcium channel blockers in spontaneously hypertensive rats.
    Vaja V; Ochodnicky P; Krenek P; Klimas J; Bajuszova Z; Kyselovic J
    Eur J Pharmacol; 2009 Oct; 619(1-3):85-91. PubMed ID: 19683522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension.
    Preston IR; Klinger JR; Landzberg MJ; Houtchens J; Nelson D; Hill NS
    Chest; 2001 Sep; 120(3):866-72. PubMed ID: 11555522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
    McLaughlin VV; Genthner DE; Panella MM; Rich S
    N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vasodilator therapy for primary pulmonary hypertension in children.
    Barst RJ; Maislin G; Fishman AP
    Circulation; 1999 Mar; 99(9):1197-208. PubMed ID: 10069788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose response to inhaled nitric oxide in pediatric patients with pulmonary hypertension and acute respiratory distress syndrome.
    Nakagawa TA; Morris A; Gomez RJ; Johnston SJ; Sharkey PT; Zaritsky AL
    J Pediatr; 1997 Jul; 131(1 Pt 1):63-9. PubMed ID: 9255193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of calcium channel blockers in the treatment of hypertension.
    Halperin AK; Cubeddu LX
    Am Heart J; 1986 Feb; 111(2):363-82. PubMed ID: 3511651
    [No Abstract]   [Full Text] [Related]  

  • 37. Role of calcium antagonists in the treatment of essential hypertension.
    Klein W; Brandt D; Vrecko K; Härringer M
    Circ Res; 1983 Feb; 52(2 Pt 2):I174-81. PubMed ID: 6831651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemodynamic effects of nifedipine at rest and during exercise in primary pulmonary hypertension.
    Olivari MT; Levine TB; Weir EK; Cohn JN
    Chest; 1984 Jul; 86(1):14-9. PubMed ID: 6734275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Favorable response of pulmonary hypertension in patients with chronic obstructive airway disease treated with diltiazem].
    Gassner A
    Schweiz Med Wochenschr; 1984 Mar; 114(10):332-7. PubMed ID: 6710104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapy of primary pulmonary arterial hypertension: current status].
    Solèr M
    Schweiz Med Wochenschr; 1994 Oct; 124(39):1701-7. PubMed ID: 7939536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.